Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies — a EuroFlow study

The standardized EuroFlow protocol, including CD19 as primary B‐cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) patients treated with chemotherapy. We developed and validated an alternative gatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Verbeek, Martijn W. C., Buracchi, Chiara, Laqua, Anna, Nierkens, Stefan, Sedek, Lukasz, Flores‐Montero, Juan, Hofmans, Mattias, Sobral de Costa, Elaine, Nováková, Michaela, Mejstrikova, Ester, Barrena, Susana, Kohlscheen, Saskia, Szczepanowski, Monika, Kulis, Jan, Oliveira, Elen, Jugooa, Romana, de Jong, Anja X., Szczepanski, Tomasz, Philippé, Jan, van Dongen, Jacques J. M., Orfao, Alberto, Brüggemann, Monika, Gaipa, Giuseppe, van der Velden, Vincent H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy–Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299641/
https://www.ncbi.nlm.nih.gov/pubmed/34881427
http://dx.doi.org/10.1111/bjh.17992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299641/
https://www.ncbi.nlm.nih.gov/pubmed/34881427
http://dx.doi.org/10.1111/bjh.17992

Ejemplares similares